Skip to content

Effects of repetitive transcranial magnetic stimulation on cognition and brain function in patients with mild to moderate Alzheimer's disease

Effects of repetitive transcranial magnetic stimulation on cognition and brain function in patients with mild to moderate Alzheimer's disease

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200055107
Enrollment
Unknown
Registered
2022-01-01
Start date
2022-01-01
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease (AD)

Interventions

Experimental group:rTMS stimulation
Control group:rTMS pseudostimulation

Sponsors

Beijing Geriatric Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Clinically diagnosed or probable AD patients, MMSE score between 10-26 points, and a diagnosis based on head imaging. Disease duration within 10 years. 2. Aged >= 60 years, gender is not limited, and those who can cooperate with rTMS and brain functional magnetic resonance examination have no contraindications. 3. If you are taking AD drugs, you need to take the drug for >=4 weeks, and there is no drug dose adjustment during the treatment period. 4. The patients' guardians agree to participate in this study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. There are contraindications for transcranial magnetic stimulation: such as those with metal implants such as pacemakers, coronary stents and aneurysm clips, and those with ferromagnetic materials such as cochlear implants; 2. Combined with functional failure and critical illness of important organs (heart, lung, liver, kidney, etc.); 3. Long-term alcoholism and drug abuse; 4. Severe hearing-impaired persons; 5. Those with a history of organic mental illness, infectious diseases, traumatic brain injury and surgery; 6. Those with a history of epilepsy; 7. Those who are undergoing other clinical trials.

Design outcomes

Primary

MeasureTime frame
Alzheimer's Disease Rating Scale - Cognitive Scale;

Secondary

MeasureTime frame
Mini-Mental State Examination Scale;Montreal Cognitive Assessment Scale;Neuropsychiatric Scale;Barthel Index;Resting-state fMRI;Adverse reactions;

Countries

China

Contacts

Public ContactHu Yueqing

Beijing Geriatric Hospital

hyqing1987@163.com+86 10 83183801

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026